Spots Global Cancer Trial Database for ATG Plus PTCy vs ATG for CGVHD Prophylaxis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ATG Plus PTCy vs ATG for CGVHD Prophylaxis
Official Title: A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
Study ID: NCT04202835
Study Description
Brief Summary: A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Detailed Description: Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Kinghorn Cancer Centre, St Vincent's Health Network, Darlinghurst, New South Wales, Australia
Royal North Shore Hospital, St. Leonards, New South Wales, Australia
Australasian Leukaemia and Lymphoma Group, Melbourne, Victoria, Australia
CancerCare Manitoba, Winnipeg, Manitoba, Canada
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada
Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada
London Health Sciences Centre, London, Ontario, Canada
Hôpital de l'Enfant-Jésus, Québec City, Quebec, Canada
Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
Contact Details
Name: Irwin R Walker, MBBS
Affiliation: McMaster University
Role: PRINCIPAL_INVESTIGATOR
Name: Kristjan Paulson, MD
Affiliation: CancerCare Manitoba
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
